Job Detail

Description

Summary:

Seattle Genetics submitted a Marketing Authorization Application in January 2020 to EMA for tucatinib, a tyrosine kinase inhibitor (TKI), for HER2+ metastatic breast cancer patients. in Europe. Currently, Seattle Genetics is building its infrastructure in Europe, which includes a group of operating affiliates located in different countries, that will allow support the commercialization of tucatinib and advancing its product pipeline.

In this role, you will lead the European HEOR Strategy development and implementation for the designated oncology pipeline. European HEOR strategy will also be one of the fundamental parts of the overall European Value Access and Pricing Strategy. Specifically, Director, HEOR, Europe will lead efforts in building up the necessary HEOR evidence base in alignment with Global HEOR and Value Access and Pricing teams to ensure European HTA requirements are met. The position will be critical in ensuring European HTA requirements are communicated strategically within the company as well securing the right evidence base to support the value proposition. This position will report into the Head of Value Access and Pricing, Europe. 

Principal Responsibilities:

• Formulates clear value proposition that aligns the evidence base to European payer and HTA landscapes


• Develops European HEOR strategy to ensure optimal access outcomes with key HTA bodies across Europe as well as to support the value of products across their lifecycles


• Provides input to relevant global workstreams such as HEOR, GVAP and others


• Monitors HTA requirements and changing regulations, including emerging trends


• Contributes to development of access and pricing strategies to secure/maintain access at optimal conditions across Europe


• Oversees building and/or adaptation of HTA models to demonstrate the value proposition in Europe as well as in affiliates


• Initiates HEOR and RWE studies in Europe to ensure the value proposition is supported by strong evidence base


• Provides input to global and local HEOR and RWE studies


• Coordinates European HTA submissions in close collaboration with local VAP Directors and alignment with global GVAP organization


• Establishes European functional and cross-functional platforms to ensure HEOR input is shared with all relevant stakeholders in affiliate, regional and global levels


• Provides HEOR input to clinical and medical organization to ensure HTA perspective is represented in clinical development plans as well as in all post-marketing medical studies


• Provides advice and support to various units within Seattle Genetics’ commercial and non-commercial organization in regional, affiliate and global levels


• Works independently and cross-functionally to help the overall company goals and objectives are accomplished


• Advances a positive spirit of partnership and collaboration with all relevant internal and external stakeholders


• Exercises mature and reliable judgment while enjoying the company’s enthusiastic and fast-paced environment

Qualifications:

• Master’s degree or higher in the field of Health Economics, Public Health, Economics or relevant field. PhD will be an advantage.


• At least 8 years of relevant experience in pharma or biotech environment


• Direct experience with Health Economic model development or adaptation


• Direct experience with HTA submissions is required. Experience with both cost-effectiveness and benefit archetypes will be an advantage


• Direct experience with RWE


• Excellent communication and negotiation skills


• Business fluency in English